Afatinib + bevacizumab combination therapy in <scp><i>EGFR</i></scp>‐mutant <scp>NSCLC</scp> patients with osimertinib resistance: Protocol of an <scp>open‐label</scp>, phase <scp>II</scp>, multicenter, <scp>single‐arm</scp> trial
Thoracic cancer